CTOs on the Move

Immantics

www.immatics.com

 
Immatics Biotechnologies is a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer. Cancer immunotherapy is still severely constrained by the lack of novel targets. Immatics overcomes this by applying its target discovery engine XPRESIDENT® to identify and validate antigens specific to cancer cells. These antigens, also called Tumor-Associated Peptides (TUMAPs), are able to activate T cells which are responsible for identifying and destroying cancer cells. These well characterized TUMAPs can be used as targets for all of the most promising cancer immunotherapy approaches including Adoptive Cell Therapies (ACT), soluble T Cell Receptors (TCRs), Antibodies ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.immatics.com
  • 7000 Fannin Suite 2115, 2120
    Houston, TX USA 77030
  • Phone: 346.204.5400

Executives

Name Title Contact Details

Funding

Immantics raised $40.3M on 09/02/2015

Similar Companies

Glycomine

There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.

Arsanis Inc

Arsanis is a leader in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. Monoclonal antibodies have transformed the treatment of a wide range of diseases from cancer to immune system disorders. In infectious diseases, mAbs can target directly specific pathogens or their virulence mechanisms to avoid pathogenic processes in the infected individual, including resistant strains that give rise to serious infections. Unlike traditional antimicrobials that often target both pathogenic and non-pathogenic organisms in a non-specific way (e.g., broadly killing all Gram-positive bacteria), Arsanis` monoclonal antibodies selectively focus on specific pathogens and pathogenic processes. These targeted immunotherapies address critical infections while minimizing the collateral damage from antimicrobial overuse, resistance, and microbiome disruption. We believe that the ability to selectively and safely target causative pathogens provides a new way of preventing and treating infections in high-risk patients, and can generate both clinical and health economic benefits to patients and providers, ushering in a new era in infection prevention and management.

TissueTech

TissueTech, Inc is a Biotechnology company headquartered in Miami, FL. TissueTech, Inc. is a leader in regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. TissueTech offers its portfolio of amniotic membrane and umbilical cord-based tissue and device products through its commercial entities: BioTissue, Inc: the industry leader in regenerative tissue therapies for ocular surface diseases and disorders. Amniox Medical: a leading technology provider to the musculoskeletal and wound care markets.

Seed IP

Seed IP is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Epirium Bio

Epirium Bio is a clinical-stage biopharmaceutical company developing therapeutics that promote mitochondrial biogenesis and function through a novel mechanism of action discovered by the company.